Shares of DaVita HealthCare Partners Inc. (NYSE:DVA) saw strong trading volume on Friday . 3,519,496 shares were traded during trading, an increase of 258% from the previous session’s volume of 981,810 shares.The stock last traded at $77.91 and had previously closed at $77.58.

Several analysts have recently issued reports on the company. Jefferies Group reiterated a “buy” rating on shares of DaVita HealthCare Partners in a research note on Monday, April 4th. Wells Fargo & Co. reiterated a “buy” rating on shares of DaVita HealthCare Partners in a research note on Saturday, June 4th. Robert W. Baird reiterated a “buy” rating on shares of DaVita HealthCare Partners in a research note on Sunday, May 8th. Susquehanna upped their price target on DaVita HealthCare Partners from $70.00 to $78.00 and gave the stock a “neutral” rating in a research note on Wednesday, April 6th. Finally, TheStreet upgraded DaVita HealthCare Partners from a “hold” rating to a “buy” rating in a research note on Wednesday, May 4th. One research analyst has rated the stock with a sell rating, five have assigned a hold rating and six have assigned a buy rating to the stock. The company currently has a consensus rating of “Hold” and an average target price of $78.88.

The stock has a market capitalization of $16.09 billion and a PE ratio of 34.95. The company’s 50-day moving average is $76.70 and its 200-day moving average is $72.31.

DaVita HealthCare Partners (NYSE:DVA) last released its quarterly earnings results on Wednesday, May 4th. The company reported $0.92 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.86 by $0.06. The firm earned $3.58 billion during the quarter, compared to analyst estimates of $3.51 billion. During the same period in the prior year, the business earned $0.86 EPS. The business’s revenue for the quarter was up 8.9% compared to the same quarter last year. Equities analysts expect that DaVita HealthCare Partners Inc. will post $3.95 earnings per share for the current year.

In other news, CEO Dennis Kogod sold 40,048 shares of the firm’s stock in a transaction dated Tuesday, May 10th. The stock was sold at an average price of $76.25, for a total value of $3,053,660.00. Following the completion of the transaction, the chief executive officer now owns 92,716 shares in the company, valued at approximately $7,069,595. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Roger Valine sold 8,220 shares of the firm’s stock in a transaction dated Thursday, May 12th. The shares were sold at an average price of $76.34, for a total value of $627,514.80. Following the completion of the transaction, the director now owns 18,324 shares of the company’s stock, valued at approximately $1,398,854.16. The disclosure for this sale can be found here.

Other institutional investors recently made changes to their positions in the company. Advantus Capital Management Inc boosted its position in shares of DaVita HealthCare Partners by 0.6% in the fourth quarter. Advantus Capital Management Inc now owns 15,975 shares of the company’s stock valued at $1,114,000 after buying an additional 92 shares during the last quarter. Mark Sheptoff Financial Planning LLC boosted its position in shares of DaVita HealthCare Partners by 0.3% in the fourth quarter. Mark Sheptoff Financial Planning LLC now owns 37,937 shares of the company’s stock valued at $2,645,000 after buying an additional 100 shares during the last quarter. Utah Retirement Systems boosted its position in shares of DaVita HealthCare Partners by 0.3% in the fourth quarter. Utah Retirement Systems now owns 31,618 shares of the company’s stock valued at $2,204,000 after buying an additional 100 shares during the last quarter. Cambridge Investment Research Advisors Inc. boosted its position in shares of DaVita HealthCare Partners by 2.7% in the fourth quarter. Cambridge Investment Research Advisors Inc. now owns 20,126 shares of the company’s stock valued at $1,403,000 after buying an additional 523 shares during the last quarter. Finally, ProShare Advisors LLC boosted its position in shares of DaVita HealthCare Partners by 3.1% in the fourth quarter. ProShare Advisors LLC now owns 29,287 shares of the company’s stock valued at $2,042,000 after buying an additional 891 shares during the last quarter.

DaVita HealthCare Partners Inc is a provider of kidney care services. The Company operates Kidney Care division and HealthCare Partners (HCP) division. Its segments include U.S. dialysis and related lab services, HCP and Other-Ancillary services and strategic initiatives. Its Kidney Care division is a provider of dialysis services in the United States, treating patients with chronic kidney failure and end stage renal disease (ESRD).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.